OMEN
Prevention and early detection are two key strategies for countering the growing strain on the healthcare system. The Health Data Use Act (GDNG) and the introduction of Section 25b of the German Social Code, Book V (SGB V) in 2024 resulted in the establishment of a legal framework that empowers statutory health insurance providers to identify individual health risks, including specific risks of cancer, by examining billing data. The OMEN project (Assessment of Individual Cancer Risks: Development and Evaluation of Prediction Models Using Health Insurance Data) takes advantage of this new opportunity and examines whether cancer can appropriately serve as a concrete use case for Section 25b of the German Social Code, Book V (SGB V). To this end, the Leibniz Institute for Prevention Research and Epidemiology in Bremen (BIPS) is developing and validating AI-supported prediction models for estimating individual cancer risk (incidence and recurrence) based on routine statutory health insurance data. This data is approximately covering 20% of the German population over a period of nearly two decades. Furthermore, the German Cancer Society’s Department of Health Services Research is investigating the acceptance of potential risk-adapted information by health insurance providers. This will include both insured individuals (through focus groups and standardized surveys) and primary care physicians and oncology providers. The project’s findings could contribute to an evidence-based evaluation of the potential of Section 25b of the German Social Code, Book V (SGB V) for risk-adapted cancer prevention and early detection.
Involved Institutions
Leibniz Institute for Prevention Research and Epidemiology – BIPS GmbH, Clinical Epidemiology
German Cancer Society (DKG)
Techniker Krankenkasse
Funding
Innovation Committee of the Joint Federal Committee
Duration
January 2026 – December 2028
More about the project
https://innovationsfonds.g-ba.de/projekte/omen.771#projektleitung-und-konsortialpartner
